These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8658693)

  • 1. OKT3 rescue therapy for 63 refractory rejections in 405 renal allografts.
    Uchida K; Namii Y; Tominaga Y; Haba T; Tanaka H; Ichimori T; Uemura O; Morozumi K; Hayashi S; Yokoyama J; Takagi H
    Transplant Proc; 1996 Jun; 28(3):1358-9. PubMed ID: 8658693
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
    Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimization of cyclosporine monotherapy--long-term graft function.
    Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
    Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
    [No Abstract]   [Full Text] [Related]  

  • 7. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
    VanderWerf BA
    Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
    Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
    Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
    Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 11. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
    Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
    Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined high and low dosing of OKT3 for treatment of rejection episodes in renal transplants.
    Schweizer RT; Bartus S; Hull D; Perdrizet G; Roper L
    Transplant Proc; 1994 Dec; 26(6):3141. PubMed ID: 7998094
    [No Abstract]   [Full Text] [Related]  

  • 13. OKT3 in renal allografts: survival and complications.
    D'Souza RJ; Kwan JT; Chang R; Bending MR
    Clin Nephrol; 1999 Apr; 51(4):257-8. PubMed ID: 10230561
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of steroid resistant acute rejection after renal transplantation.
    Oh CK; Kim YS; Kim MS; Kim SI; Park K
    Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
    [No Abstract]   [Full Text] [Related]  

  • 15. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe allograft dysfunction after OKT3-induced human herpes virus-6 reactivation.
    Jacobs U; Ferber J; Klehr HU
    Transplant Proc; 1994 Dec; 26(6):3121. PubMed ID: 7998088
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
    Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of cyclosporine rescue therapy in steroid resistant rejections.
    Sharma RK; Elhence R; Kher V; Gupta A; Kumar A; Bhandari M; Agrawal S
    Transplant Proc; 1994 Oct; 26(5):2556-7. PubMed ID: 7940789
    [No Abstract]   [Full Text] [Related]  

  • 19. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
    van Son WJ; van den Berg AP; The TH; Tegzess AM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term results of OKT3-treated renal transplant recipients.
    Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K
    Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.